From the lab bench to the deal table.

Most academic founders and technology transfer offices face the same question first: is this discovery worth spinning out, or is licensing the smarter path? The answer is rarely obvious from inside the lab. It requires a commercial assessment of the unmet need the discovery addresses, the differentiation it can sustain, and the development pathway that makes it legible to investors -- not just to scientific peers.

The critical questions at this stage: does the asset have a defensible IP position? Is there a realistic path to clinical or commercial validation? Who would ultimately acquire or fund this, and what would they need to see? Without answers to these questions, a spinout roadmap is just a structure without a foundation.

Having a legal structure is not the same as having an investable asset. Biotech investors do not fund science -- they fund a credible path from today's data to a future exit. That path needs to be visible: which milestones create value, which ones retire the risks investors care about most, and what the company looks like at the moment a pharma acquirer or VC writes a serious check.

The architecture underneath the pitch deck -- the exit scenario, the milestone map tied to value inflection points, the capital ask framed as probability purchased rather than activity funded -- is what determines whether a Series A conversation opens or closes. Most founding teams build the deck first. The architecture comes last, when it should come first.

The gap between a good company and a funded company is almost never scientific. It is structural: milestones described as activities rather than value inflection points, a capital ask disconnected from what each euro actually buys, a pitch architecture built for scientific peers rather than for capital allocators.

Capital for a European biotech startup comes from two distinct sources -- and the right strategy almost always combines both. Equity funding from VC or corporate venture gives speed and network. Non-dilutive funding through instruments like the EIC Accelerator or Horizon Europe preserves ownership and de-risks the asset before the next equity round. Each source requires a different architecture: a pitch deck for a VC partner, a proposal built around commercial logic rather than grant logic for the EIC. The sequencing of the two -- which comes first, which de-risks what for whom -- is itself a strategic decision.

Pharma business development teams evaluate hundreds of out-licensing opportunities per year and pass on most of them -- not because the science is weak, but because the asset is not presented in the language of their decision criteria. The question a pharma BD team asks is not 'is this good science?' It is: does this asset fit our pipeline gap, at this stage, with this data package, at a price we can justify to our investment committee?

Answering that question before the first partnering conversation requires a partnerability assessment: an honest audit of what the asset can credibly claim, what data gaps would kill a deal in due diligence, and what the Target Licensing Profile looks like from the buyer's side. The data narrative, the entry point, the deal structure -- all of it needs to be built around pharma decision criteria, not around the scientific story that got the asset to this stage.

Not sure which stage you are at?

A 30-minute call is enough to map your position and identify the most critical gap.